This novel compound has demonstrated comparable stability and heightened efficacy for eliminating lung cancer and prostate cancer cells, positioning it as a potent candidate for developing targeted therapy against E2F1-induced tumors (Shaik et al., 2018). Here, E2F1 is linked to prostate carcinoma.